Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm biomarker study of ALZ-801 in APOE4 carriers with early Alzheimer's disease
NL-OMON56257Phase 2Recruiting
- Sponsor
- Alzheon, Inc.
- Start
- Nov 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valiltramiprosate in Alzheimer's disease (AD), sponsored by Alzheon, Inc. Primary endpoints: Change in plasma p-tau181 at Week 104, Change in hippocampal volume at Week 104 and 4 more. Started Nov 2020; status: recruiting.
02
Drugs
valiltramiprosate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON56257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56257.